|
|
|
11-50 employees
View all
|
|
Biotechnology
|
|
., Cambridge, MA, US
|
|
Join our growing team!
Alkeus Pharmaceuticals, Inc. is a late-stage biopharmaceutical company developing transformative therapeutics to address serious, progressive eye diseases that lead to blindness.
Our lead compound, ALK-001, is an oral investigational drug being developed for the treatment of Stargardt disease (STGD) and Geographic Atrophy (GA) secondary to dry age-related macular degeneration.
ALK-001 is a selectively-deuterated form of Vitamin A that slows the dimerization of Vitamin A, which is implicated in STGD, and has shown statistically-significant and clinically-meaningful efficacy in the TEASE-1 Phase 2 clinical trial. Based on these results, ALK-001 has been granted Breakthrough Therapy Designation for the treatment of Stargardt Disease.
|
Alkeus Pharmaceuticals, Inc. Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used Alkeus Pharmaceuticals, Inc. email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact Alkeus Pharmaceuticals, Inc. customer service number in your country click here to find.
Leonide Saad is the CEO of Alkeus Pharmaceuticals, Inc.. To contact Leonide Saad email at [email protected] or [email protected].
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.